Orchard Secures New Libmeldy Price In Germany
Executive Summary
Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.
You may also be interested in...
Orchard Will Launch Lenmeldy At Just Five Centers
Orchard, which Kyowa Kirin bought in October, gave Lenmeldy a $4.25m list price, exceeding the upper bound of about $3.9m set by ICER.
New Data Means Successful Joint Pricing Talks For Orchard’s Libmeldy in Europe
Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.
ICER Report Assumes $2.8m Price For Libmeldy As Orchard Gears Up For US Debut
The drug-pricing watchdog gave the gene therapy for metachromatic leukodystrophy an “A” grade for use in presymptomatic patients receiving the therapy, which already is approved in Europe.